Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

268
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
268
Obedience01:08

Obedience

35.6K
According to obedience research, we may harm others under the forceful pressures of an authority figure (Milgram, 1974). How about if the inappropriate orders were delivered with less force? The increasing interdependence between nurses and physicians compelled Hofling and his colleagues to explore nurses’ reactions to a potentially harmful medical request made by the perceived authority figure, the doctor (Hofling, Brotzman, Dalrymple, Graves, & Pierce, 1966). In this situation,...
35.6K
Ethics in Research01:56

Ethics in Research

25.6K
Today, scientists agree that good research is ethical in nature and is guided by a basic respect for human dignity and safety. However, this has not always been the case. Modern researchers must demonstrate that the research they perform is ethically sound.
25.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of β-Blockers Across the Cardiovascular Continuum: A Real-World Perception Survey (ROBUST).

The Journal of the Association of Physicians of India·2026
Same author

Bridging the Gap: Managing Hypertension in Indian Patients with Metabolic Syndrome.

The Journal of the Association of Physicians of India..·2025
Same author

Its High Time to Correct Vitamin D Levels to the Optimum.

The Journal of the Association of Physicians of India·2024
Same author

Phase IV Studies: What Clinicians Need to Know!

The Journal of the Association of Physicians of India·2024
Same author

Correlation between Stroke Risk and Systolic Blood Pressure in Patients over 50 Years with Uncontrolled Hypertension: Results from the SYSTUP-India Study.

Cardiovascular therapeutics·2021
Same author

Clinical Evidence of Evogliptin plus Metformin in Management of Type 2 Diabetes mellitus.

The Journal of the Association of Physicians of India·2021

Related Experiment Video

Updated: Feb 3, 2026

DTI of the Visual Pathway - White Matter Tracts and Cerebral Lesions
10:05

DTI of the Visual Pathway - White Matter Tracts and Cerebral Lesions

Published on: August 26, 2014

14.6K

Dabigatran - the First Approved DTI for SPAF.

Abhijit Trailokya1, J S Hiremath2

  • 1Deputy General Manager, Medical Department of Alkem laboratory, Mumbai, Maharashtra.

The Journal of the Association of Physicians of India
|October 24, 2018
PubMed
Summary

Dabigatran etexilate offers effective stroke prevention in atrial fibrillation (AF) patients, with a 150mg dose superior to warfarin for stroke reduction and a 110mg dose superior for reducing major bleeding. It provides advantages over warfarin with no required monitoring or dietary restrictions.

More Related Videos

Fiber Connections of the Supplementary Motor Area Revisited: Methodology of Fiber Dissection, DTI, and Three Dimensional Documentation
16:23

Fiber Connections of the Supplementary Motor Area Revisited: Methodology of Fiber Dissection, DTI, and Three Dimensional Documentation

Published on: May 23, 2017

11.8K
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.6K

Related Experiment Videos

Last Updated: Feb 3, 2026

DTI of the Visual Pathway - White Matter Tracts and Cerebral Lesions
10:05

DTI of the Visual Pathway - White Matter Tracts and Cerebral Lesions

Published on: August 26, 2014

14.6K
Fiber Connections of the Supplementary Motor Area Revisited: Methodology of Fiber Dissection, DTI, and Three Dimensional Documentation
16:23

Fiber Connections of the Supplementary Motor Area Revisited: Methodology of Fiber Dissection, DTI, and Three Dimensional Documentation

Published on: May 23, 2017

11.8K
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.6K

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Atrial fibrillation (AF) is a common arrhythmia with stroke as a major complication.
  • Vitamin K antagonists (VKAs) like warfarin are standard for stroke prevention in AF but have limitations.
  • Dabigatran etexilate, a direct thrombin inhibitor, is approved for stroke prevention in AF.

Purpose of the Study:

  • To evaluate the efficacy and safety of dabigatran etexilate compared to warfarin for stroke prevention in AF.
  • To highlight the advantages of dabigatran over traditional VKAs.

Main Methods:

  • The study references the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial.
  • This was a randomized clinical trial comparing dabigatran etexilate to warfarin.

Main Results:

  • The 150mg dose of dabigatran was superior to warfarin in preventing stroke or systemic embolism.
  • The 110mg dose of dabigatran was superior to warfarin in reducing major bleeding.
  • Adverse events were similar, with dyspepsia being more common with dabigatran.

Conclusions:

  • Dabigatran etexilate offers effective and safe stroke prevention in AF patients.
  • Dabigatran has advantages over VKAs, including predictable pharmacokinetics, no need for monitoring, and fewer drug-food interactions.
  • Dabigatran is the only NOAC with an approved reversal agent.